Ultra-Hypofractionated Whole-Breast Irradiation With or Without Simultaneous Integrated Boost Using Helical Tomotherapy for Early-Stage Breast Cancer: A Real-World Dosimetric and Clinical Outcome Study
Cancers · 20.03.2026 · 18 (6) · 1015
DOI: 10.3390/cancers18061015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 20.03.2026. Verfasst von Pei-Yu Hou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radiation Oncology, Department of Radiology, Far Eastern Memorial Hospital, New Taipei City 220216, Taiwan. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Far Eastern Memorial Hospital.
Abstract (Originalsprache)
Background
Ultra-hypofractionated whole-breast irradiation (WBI) delivering 26 Gy in five fractions has been established as a standard of care following the FAST-Forward trial. However, real-world data addressing advanced delivery techniques and the feasibility of incorporating a simultaneous integrated boost (SIB) remain limited.
Methods
We retrospectively analyzed 40 patients with early-stage breast cancer (pT1–2N0M0) treated with breast-conserving surgery, followed by ultra-hypofractionated WBI using helical tomotherapy. Patients received either WBI alone (26 Gy in five fractions) or WBI with an SIB to the tumor bed (29–30 Gy in five fractions). Dosimetric parameters for planning target volumes (PTVs) and organs at risk (OARs) were evaluated. Acute skin toxicity was assessed using CTCAE version 5.0.
Results
The median patient age was 55.7 years. The mean PTV V95% was 97.8%, with excellent hotspot control (PTV V105% < 5% and V107% < 2%). For left-sided tumors, the mean heart dose was 1.67 Gy, and the ipsilateral lung V8Gy remained below 15% in all patients. Acute radiation dermatitis was limited to Grade 0–1 in all cases. At a median follow-up of 14.8 months, both local control and overall survival were 100%.
Conclusions
Ultra-hypofractionated WBI delivered using helical tomotherapy, with or without SIB, demonstrates robust dosimetric quality, minimal acute toxicity, and favorable early clinical outcomes in routine clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Radiation Oncology, Department of Radiology, Far Eastern Memorial Hospital, New Taipei City 220216, Taiwan.
- Department of Computer Science and Engineering, Yuan Ze University, Taoyuan 320315, Taiwan.
- School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
ORCID-Profile: Eva Yu-Hsuan Chuang
Förderung
- Far Eastern Memorial Hospital
Zitieren
APA
Hou, P. Y., Hsieh, C. H., Yeh, H. P., & Chuang, E. Y. (2026). Ultra-Hypofractionated Whole-Breast Irradiation With or Without Simultaneous Integrated Boost Using Helical Tomotherapy for Early-Stage Breast Cancer: A Real-World Dosimetric and Clinical Outcome Study. Cancers, 18(6), 1015. https://doi.org/10.3390/cancers18061015
Vancouver
Hou PY, Hsieh CH, Yeh HP, Chuang EY. Ultra-Hypofractionated Whole-Breast Irradiation With or Without Simultaneous Integrated Boost Using Helical Tomotherapy for Early-Stage Breast Cancer: A Real-World Dosimetric and Clinical Outcome Study. Cancers. 2026;18(6):1015. doi:10.3390/cancers18061015
BibTeX
@article{Hou2026,
author = {Hou, Pei-Yu and Hsieh, Chen-Hsi and Yeh, Hsin-Pei and Chuang, Eva Yu-Hsuan},
title = {Ultra-Hypofractionated Whole-Breast Irradiation With or Without Simultaneous Integrated Boost Using Helical Tomotherapy for Early-Stage Breast Cancer: A Real-World Dosimetric and Clinical Outcome Study},
journal = {Cancers},
year = {2026},
volume = {18},
number = {6},
pages = {1015},
doi = {10.3390/cancers18061015}
}
EUVIMED